Valneva's share price has fluctuated sharply in recent weeks on news about the company's COVID-19 vaccine candidate.
(Reporting by Tassilo Hummel, editing by GV De Clercq)
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
3.492 EUR | -0.06% |
|
+4.11% | -26.02% |
07-01 | Valneva's Secures Marketing Authorization in Europe for Chikungunya Vaccine | MT |
07-01 | New semester, new state of mind | ![]() |
PARIS (Reuters) - Shares in biotech firm Valneva dropped as much as 6.9% on Tuesday after the European Union drug regulator said the firm's COVID-19 vaccine was under an EU rolling review but it was still awaiting some additional data.
Valneva's share price has fluctuated sharply in recent weeks on news about the company's COVID-19 vaccine candidate.
(Reporting by Tassilo Hummel, editing by GV De Clercq)
1st Jan change | Capi. | |
---|---|---|
-26.02% | 529M | |
+22.29% | 47.96B | |
+0.72% | 42.45B | |
+43.79% | 41.47B | |
+27.21% | 31.6B | |
+20.87% | 28.63B | |
-4.47% | 28.03B | |
+52.71% | 14.56B | |
+45.18% | 14.14B | |
+2.84% | 12.58B |